About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

TERMINATEDPhase 2

A Phase 2 Study to Evaluate the Safety and Efficacy of LOU064 in Patients With Moderate to Severe Sjögren's Syndrome

An Adaptive Phase 2 Randomized Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Multiple LOU064 Doses in Patients With Moderate to Severe Sjögren's Syndrome (LOUiSSe)

NCT04035668•Novartis Pharmaceuticals

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Sjögren Syndrome

Interventions

Remibrutinib

Placebo

Locations

26

United States

Locations (26)

Novartis Investigative Site

Boston, Massachusetts, United States

Novartis Investigative Site

Woodville, South Australia, Australia

Novartis Investigative Site

Hobart, Tasmania, Australia

Novartis Investigative Site

Clayton, Victoria, Australia

Novartis Investigative Site

Ghent, Belgium

Novartis Investigative Site

Sofia, Bulgaria

Key Dates

Start Date

July 12, 2019

Primary Completion Date

November 23, 2021

Completion Date

November 23, 2021

Last Updated

January 30, 2023

Related Studies

RECRUITINGPhase 2

A Study of RSLV-132 in Females With Sjögren's Disease

NCT06440525

Primary Sjögren Syndrome

Construction of Clinical Model of Primary Sjogren's Syndrome Combined Traditional Chinese and Western Medicine

NCT06528197

Primary Sjögren Syndrome

Eye Dryness Evaluation in Primary Sjögren's Syndrome

NCT03614299

Primary Sjögren Syndrome

COMPLETEDPhase 1

Pilot Trial of Ustekinumab for Primary Sjögren's Syndrome

NCT04093531

Primary Sjögren Syndrome

UNKNOWNPhase 1/2

68Ga-P16-093 PET/CT Imaging in the Salivary Gland

NCT06049368

Primary Sjögren Syndrome

COMPLETEDPhase 2

Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjogren's Syndrome

NCT03905525

Sjögren Syndrome

View all related studies

Sponsors

Lead Sponsor

Novartis Pharmaceuticals

Detailed Description

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 30, 2023Data synced to Clareo: April 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions